News / Health

Scant Funds, Rare Outbreaks Leave Ebola Drug Pipeline Slim

A doctor works in a laboratory on collected samples of the Ebola virus at the Center for Disease Control in Entebbe, about 37 km southwest of Uganda's capital Kampala, Aug. 2, 2012.
A doctor works in a laboratory on collected samples of the Ebola virus at the Center for Disease Control in Entebbe, about 37 km southwest of Uganda's capital Kampala, Aug. 2, 2012.
Reuters
Almost 40 years after the Ebola virus was identified in humans by scientists in a microbiology laboratory in Belgium, pharmaceutical researchers have yet to develop an effective drug or vaccine to fight it.

Part of the problem is that the deadly virus is rare and its victims are often poor people living in rural areas of Africa without well-functioning health systems. But there is also little incentive for major pharmaceutical companies to invest in medical solutions when there is little chance of a return.

The number of doses sold is likely to be small and many health officials believe the virus and its death toll could be better controlled with good basic hygiene and the eradication of dangerous bushmeat consumption. Yet there is a drug development pipeline, of sorts, out there - mainly funded by the U.S. government which fears such deadly viruses might one day be developed into bioweapons.

"We can do basic research quite cheaply, but when you move from that to trying to develop drugs and vaccines, you get into the need for clinical trials and they are very costly - which is where you would normally start to engage with Big Pharma," said Jonathan Ball, a professor of molecular virology at Britain's University of Nottingham. "And clearly they are not going to invest unless there is likely to be some sort of decent return."

Discovered in 1976 after an outbreak in the Democratic Republic of Congo, then
This colorized transmission electron micrograph (TEM) obtained March 24, 2014 from the Centers for Disease Control(CDC) in Atlanta, Georgia, reveals some of the ultrastructural morphology displayed by an Ebola virus virion. (AFP PHOTO / CDC / Cynthia Gold)This colorized transmission electron micrograph (TEM) obtained March 24, 2014 from the Centers for Disease Control(CDC) in Atlanta, Georgia, reveals some of the ultrastructural morphology displayed by an Ebola virus virion. (AFP PHOTO / CDC / Cynthia Gold)
x
This colorized transmission electron micrograph (TEM) obtained March 24, 2014 from the Centers for Disease Control(CDC) in Atlanta, Georgia, reveals some of the ultrastructural morphology displayed by an Ebola virus virion. (AFP PHOTO / CDC / Cynthia Gold)
This colorized transmission electron micrograph (TEM) obtained March 24, 2014 from the Centers for Disease Control(CDC) in Atlanta, Georgia, reveals some of the ultrastructural morphology displayed by an Ebola virus virion. (AFP PHOTO / CDC / Cynthia Gold)
Zaire, Ebola causes a severe hemorrhagic fever where victims suffer vomiting, diarrhea and both internal and external bleeding.

In an outbreak in Guinea in West Africa, about 86 suspected cases have been reported, with 62 deaths, according to the World Health Organization. Investigations are going on into reported cases in Liberia and Sierra Leone along the border with Guinea.

Bioweapon Fears

"Ebola virus is one of the deadliest killers known," said Ben Neuman, a virologist at Britain's University of Reading. "[It] is one of the things that keeps public health officials up at night. If this virus spread between people more easily, it would probably be more deadly than the black plague. Fortunately, up to this point, it has not."

So while for drugmakers there is little commercial future in Ebola, some research groups in the United States are working in conjunction with the U.S. government to find treatments.

In March, the University of Texas and three other organizations got $26 million in funding from the U.S. National Institutes of Health to find a cure for Ebola and another deadly virus Marburg in case they are ever used for bioterrorism in the United States.

Tekmira Pharmaceuticals, which teamed up with the U.S. Department of Defense on an injectable drug treatment for Ebola, started an initial Phase I trial in healthy volunteers in January.

Several small biotech companies and U.S. university departments are also developing potential vaccines, but this work has yet to advance from animal studies into clinical trials in humans - so any use in people now would be very risky.

U.S.-based Inovio and privately held Vaxart are among those with experimental vaccines in animal testing, while GlaxoSmithKline last year acquired Swiss vaccine firm Okairos with an early-stage Ebola product.

"There are a few experimental vaccines, but the question is whether anybody would take on the costs of manufacture based on the likely number of doses they would eventually sell," said Ian Jones, a professor of virology at Reading University. "The numbers of people infected are low, and at the end of the day somebody has to fund the production of a drug or vaccine. As things stand that is unlikely."

Drug Trials

The immense difficulty and high cost of conducting human clinical trials for a potential drug or vaccine are prohibitive, experts point out, since Ebola cases are generally far-flung, rare and unpredictable.

"For a start there are simply not enough patients and you wouldn't know when the next outbreak was going to happen," said Jones. "Even then you couldn't guarantee there would be enough people to run a trial. Which means you would have to go from the best evidence in animal models."

Some scientists say the current outbreak in Guinea could be an opportunity to do just that - offering a chance to push the field forward and test potential vaccines or drugs.

Thomas Geisbert at the University of Texas Medical Branch is working on a vaccine known as vesicular stomatitis virus-based Ebola vaccine, or VSV, which he said had shown 100 percent efficacy in tests on animals.

The shot, which has not gone through clinical trials in humans, could, he said, be issued on "compassionate grounds" to people in Guinea at risk in the current Ebola outbreak.

"You have to reach a balance between advancing science, medical ethics and saving lives," he told Reuters. "It's not easy, but how many people faced with the prospect of near certain death would opt to take their  chances with the virus?"

You May Like

In China, Mixed Signals on Ebola Controls

How authorities are monitoring at-risk individuals remains unclear, including whether there are quarantines for Chinese health workers returning from West Africa More

Video Women Voters Anxious Ahead of US Elections

Analysts say if women are focused on national security, it could be bad news for Democrats More

Solar's Future Looks Brighter

New technology and dropping prices are contributing to a surge in solar power More

This forum has been closed.
Comment Sorting
Comments
     
by: Hassan Koroma from: Sierria Leone
March 28, 2014 7:35 PM
Thanks to the texas university for the research for the curement of the ebola virus. We're now on prayers for God not to bring that disaster in our country.

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Women Voters Anxious Ahead of US Electionsi
X
October 31, 2014 4:10 AM
Public opinion polls show American voters are deeply dissatisfied with their government and anxious about threats from abroad. This is especially true for a key voting group both Republicans and Democrats are trying hard to win over: women. Analysts say if women are focused on national security, it could be bad news for Democrats, with majority control of the Senate at stake. VOA’s Cindy Saine looks at the crucial role women voters will play in deciding the elections.
Video

Video Women Voters Anxious Ahead of US Elections

Public opinion polls show American voters are deeply dissatisfied with their government and anxious about threats from abroad. This is especially true for a key voting group both Republicans and Democrats are trying hard to win over: women. Analysts say if women are focused on national security, it could be bad news for Democrats, with majority control of the Senate at stake. VOA’s Cindy Saine looks at the crucial role women voters will play in deciding the elections.
Video

Video Victorious Secularists Face Challenge to Form Government in Tunisia

Official results from Tunisia show the Islamist Ennahda party has failed to win the second free election since the so-called "Arab Spring" uprising in 2011. Ennahda, which handed power to a government of technocrats pending the elections, lost out to the secular party Nidaa Tounes. Henry Ridgwell reports from London that the relatively peaceful poll offers some hope in a volatile region.
Video

Video Africa Tells its Story Through Fashion

In Africa, Fashion Week is a riot of colors, shapes, patterns and fabrics - against the backdrop of its ongoing struggle between nature and its fast-growing urban edge. How do these ideas translate into needle and thread? VOA’s Anita Powell visited this year’s Mercedes Benz Fashion Week Africa in Johannesburg to find out.
Video

Video Smugglers Offer Cheap Passage From Turkey to Syria

Smugglers in Turkey offer a relatively cheap passage across the border into Syria. Ankara has stepped up efforts to stem the flow of foreign fighters who want to join Islamic State militants fighting for control of the Syrian border city of Kobani. But porous borders and border guards who can be bribed make illegal border crossings quite easy. Zlatica Hoke has more.
Video

Video China Political Meeting Seeks to Improve Rule of Law

China’s communist leaders will host a top level political meeting this week, called the Fourth Plenum, and for the first time in the party’s history, rule of law will be a key item on the agenda. Analysts and Chinese media reports say the meetings could see the approval of long-awaited measures aimed at giving courts more independence and include steps to enhance an already aggressive and high-reaching anti-corruption drive. VOA’s Bill Ide has more from Beijing.
Video

Video After Decades of Pressure, Luxembourg Drops Bank Secrecy Rules

European Union finance ministers have reached a breakthrough agreement that will make it more difficult for tax cheats to hide their money. The new legislation, which had been blocked for years by countries with a reputation as tax havens, was approved last week after Luxembourg and Austria agreed to lift their vetoes. But as Mil Arcega reports, it doesn’t mean tax cheats have run out of places to keep their money hidden.
Video

Video Kobani Refugees Welcome, Turkey Criticizes, US Airdrop

Residents of Kobani in northern Syria have welcomed the airdrop of weapons, ammunition and medicine to Kurdish militia who are resisting the seizure of their city by Islamic State militants. The Turkish government, however, has criticized the operation. VOA’s Scott Bobb reports from southeastern Turkey, across the border from Kobani.

All About America

AppleAndroid